Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study

Autor: Dongyang Yang, Jaime O. Claudio, Elliot Charles Smith, Aniket Bankar, Jose Mario Capo-Chichi, James A. Kennedy, Caroline J McNamara, Hassan Sibai, Hubert Tsui, Nancy Siddiq, Shabbir M.H. Alibhai, Verna Cheung, Dawn Maze, Vikas Gupta, Sarah Malik, Wei Xu, Andrea Arruda

Publikováno v: British Journal of Haematology

Summary There is limited understanding of the impact of frailty on clinical outcomes in patients with myelofibrosis (MF). In this retrospective cohort study on 439 chronic phase MF patients [mean age: 68·7 ± 12 years; median follow‐up: 3·4 years

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63017bdb3585414e7bcbce96bb68af4f
http://europepmc.org/articles/PMC8361997

Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes: a Nordic Lymphoma Group study

Autor: Tarec Christoffer El-Galaly, Tove Wästerlid, Sandra Eloranta, Ingrid Glimelius, Karin E. Smedby, Henrik Frederiksen, Kim Oren Gradel

Publikováno v: Wästerlid, T, Oren Gradel, K, Eloranta, S, Glimelius, I, El-Galaly, T C, Frederiksen, H & Smedby, K E 2021, ' Clinical characteristics and outcomes among 2347 patients aged ≥85 years with major lymphoma subtypes : a Nordic Lymphoma Group study ', British Journal of Haematology, vol. 192, no. 3, pp. 551-559 . https://doi.org/10.1111/bjh.17250
British Journal of Haematology

There is a lack of data regarding treatment and prognosis for the growing group of oldest old patients with lymphoma. Therefore, we studied 2347 patients aged >= 85 years from the Danish and Swedish lymphoma registers 2000-2016 (Denmark) and 2007-201

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1880b89cb7095d1f077f46fa28efee7b
https://doi.org/10.1111/bjh.17250

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect ® MM Registry

Autor: Brian G.M. Durie, Amani Kitali, Robert M. Rifkin, Howard R. Terebelo, Rafat Abonour, Kathleen Toomey, Cristina Gasparetto, Sundar Jagannath, Sikander Ailawadhi, James L. Omel, Amit Agarwal, James W. Hardin, Mohit Narang, Lynne I. Wagner, Hans C. Lee, Shankar Srinivasan

Publikováno v: British Journal of Haematology

Content: CART QUOL is a study that has recently opened in the University Hospital of Wales Cardiff and was designed and set up by the Chief Investigator Emma Williams. Emma is a nurse and has been working within haematology since 2009. The study will

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcc706c88ddb68a6ed03e0c8bc8905ce
https://doi.org/10.1111/bjh.17131

Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Autor: Mels Hoogendoorn, Rineke B L Leys, Dana A. Chitu, Okke de Weerdt, Hanneke C. Kluin-Nelemans, Eva de Jongh, Rien van Marwijk Kooij, Robby E. Kibbelaar, Mars B. van 't Veer, Michel van Gelder, Monique C. Minnema, Marie Josee Kersten, Josée M. Zijlstra, Daphne de Jong, Jeanette K. Doorduijn, M.A. MacKenzie, Tjeerd J. F. Snijders, Pieternella J. Lugtenburg, Lara H Böhmer

Publikováno v: Doorduijn, J K, Zijlstra, J M, Lugtenburg, P J, Kersten, M J, Böhmer, L H, Minnema, M C, MacKenzie, M A, van Marwijk Kooij, R, de Jongh, E, Snijders, T J F, de Weerdt, O, van Gelder, M, Hoogendoorn, M, Leys, R B L, Kibbelaar, R E, de Jong, D, Chitu, D A, Van’t Veer, M B & Kluin-Nelemans, H C 2020, ' Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial ', British Journal of Haematology, vol. 190, no. 3, pp. 385-393 . https://doi.org/10.1111/bjh.16567
British Journal of Haematology, 190(3), 385-393. Wiley
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell
British Journal of Haematology, 190, 3, pp. 385-393
British Journal of Haematology
British Journal of Haematology, 190, 385-393
British Journal of Haematology, 190(3), 385-393. Wiley-Blackwell Publishing Ltd
British journal of haematology, 190(3), 385-393. Wiley-Blackwell

Contains fulltext : 225496.pdf (Publisher’s version ) (Open Access) Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a4ea79a8fe4dc5d93bcc8bbeecbc57
https://doi.org/10.1111/bjh.16567

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia

Autor: Nicola E. Potter, Manohursingh Runglall, Adam Ivey, Anthony P. Schwarer, Kavita Raj, Phillip C. Nguyen, Nigel H. Russell, Chun Yew Fong, Annie‐Louise Latif, Andrew H. Wei, Tse-Chieh Teh, Andrew Grigg, Nicholas James Cummings, Ing Soo Tiong, Richard Dillon, David Taussig

Publikováno v: British Journal of Haematology

Summary Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 mut measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677b939db6f3dc479a1f8bc86d097fdb
https://doi.org/10.1111/bjh.16722